Rosuvastatin is a member of the drug class of statins, lowering high cholesterol and triglycerides in certain patients. It is recommended to be used only after other measures such as diet and exercise.
It is used to slow atherosclerosis (narrowing of the arteries) in patients with high blood cholesterol levels.
It is also used in certain patients to reduce the risk of heart attack or stroke.
Mechanism of action:
It acts by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
If one allergic to any ingredient in Rosuvastatin.
In pregnancy and breast feeding.
In active liver disease or abnormal liver function.
If one addicted to alcohol or a history of alcohol abuse.
More serious side effect are muscle pain, tenderness, lack of energy, fever, chest pain, jaundice, dark colored, or foamy urine, pain in the upper right part of the abdomen, loss of appetite, flu-like symptoms, sore throat, chills.
Rosuvastatin may have negative interaction with following drugs:
CompositionProgesterone (100 mg) SALT INFORMATIONProgesterone (100 mg) TYPICAL USAGE Recurrent miscarriage, amenorrhoea, abnormal uterine bleeding, palliative treatment of advanced, inoperable endometrial carcinoma SIDE EFFECTS GI disturbances, increased appetite, weight gain or loss, oedema, acne, allergic skin rashes, urticaria, mental depression, discomfort in breast, cough, dyspnoea. DRUG INTERACTION Hydroxyprogesterone caproate is known to interact with other drugs like carbamazepine, phenytoin, ciclosporin. MECHANISM OF ACTION Hydroxyprogesterone caproate stimulates luteal actions, changes in uterus and vagina as seen in early pregnancy. It also has prolonged uterotrophic effect. Contractile response of the myometrium to oxytocin is inhibited.
CompositionRabeprazole (20 mg) SALT INFORMATIONRabeprazole (20 mg) TYPICAL USAGE Benign gastric and peptic ulcer. Erosive of ulcerative gastro-oesophageal reflux disease (GORD). Acid peptic disease. SIDE EFFECTS Nausea, stomach upset, skin rash, acute toxicity. DRUG INTERACTION There have been reports of an increase in the effect of the blood thinner, warfarin (Coumadin), by rabeprazole which theoretically could lead to increased bleeding. Patients taking warfarin should be monitored more frequently if they begin taking rabeprazole. Rabeprazole may reduce the elimination of cyclosporin in the liver, thereby increasing cyclosporin levels in the blood and potentially leading to cyclosporin toxicity. The absorption of certain drugs may be affected by changes in stomach acidity. Rabeprazole and other PPIs that reduce stomach acid reduce the absorption and concentration in blood ofketoconazole (Nizoral) and increase the absorption and concentration in blood of digoxin (Lanoxin). This may lead to reduced effectiveness of ketoconazole or increased digoxin toxicity, respectively. PPIs may decrease blood levels of atazanavir (Reyataz). MECHANISM OF ACTION Rabeprazole is an oral drug that is used for the treatment of conditions caused by acid. It is in a class of drugs called proton pump inhibitors or PPIs which block the production of acid by the stomach. Other drugs in the same class include lansoprazole (Prevacid),omeprazole (Prilosec), pantoprazole (Protonix), esomeprazole (Nexium), and dexlansoprazole (Dexilant). PPIs are used for the treatment of acid-caused conditions such as stomach and duodenal ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison Syndrome. Rabeprazole, like other PPIs, blocks the pump in the wall of the stomach that secretes acid into the stomach. By blocking the pump, the secretion of acid into the stomach is decreased, and this allows ulcers in the stomach and esophagus to heal. The FDA approved rabeprazole in August 1999.
CompositionAceclofenac (100 mg) SALT INFORMATIONAceclofenac (100 mg) TYPICAL USAGE Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. SIDE EFFECTS Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes DRUG INTERACTION May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants MECHANISM OF ACTION Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.